Detection of malignant hematopoietic cells in cerebral spinal fluid previously diagnosed as atypical or suspicious.
Detection of malignant hematopoietic cells in cerebral spinal fluid previously diagnosed as atypical or suspicious.
复制标题
检测先前诊断为非典型或可疑的脑脊液中的恶性造血细胞。
作者：
Schinstine,Malcolm;Filie,ArmandoC;Wilson,Wyndham;Stetler-Stevenson,Maryalice;Abati,Andrea
背景：造血系统恶性肿瘤累及脑脊液（CSF）可能很难仅通过形态学来证实。在细胞数量少或形态不明确的情况下，可以使用“非典型”或“可疑”的诊断。在这种情况下，这些诊断术语的意义尚未得到很好的确定。方法对2000年1月至2004年7月间已知淋巴瘤或白血病患者32例，经形态学标准初步诊断为“不典型”或“可疑”。随后对这些患者的流式细胞术（FC）和细胞学数据进行评估。结果在32例初始诊断为“非典型”或“可疑”的患者中，40.6% （n= 13）的首次和后续FC和脑脊液样本形态学评估均为阴性，随访时间长达1年。19例患者（59.4%）在随后的脑脊液样本中通过细胞学和/或FC鉴定出恶性造血细胞。结论：在既往有淋巴瘤或造血恶性肿瘤病史的患者中，大多数（59.4%）脑脊液“不典型”或“可疑”诊断的患者最终会通过细胞学和/或FC在脑脊液中发现恶性细胞。许多这样的病人可以更方便地识别与流式细胞术同时使用。癌症（癌症细胞酚）2006。2006年由美国癌症协会出版。
BACKGROUNDInvolvement of the cerebrospinal fluid (CSF) by hematopoietic malignancies may be difficult to document by morphology alone. In cases with low numbers of cells or ambiguous morphology, the diagnoses of “atypical” or “suspicious” may be used. The significance of these diagnostic terms in this scenario has not been well established.METHODSBetween January 2000 and July 2004, 32 patients with known lymphoma or leukemia and an initial diagnosis of “atypical” or “suspicious” using morphologic criteria were identified. Subsequent flow cytometry (FC) and cytologic data from these patients were evaluated.RESULTSOf the 32 patients with an initial diagnosis of “atypical” or “suspicious,” 40.6% (n= 13) had negative first and subsequent FC and morphologic evaluation of their CSF samples with follow‐up up to 1 year. Nineteen patients (59.4%) had malignant hematopoietic cells identified in subsequent CSF samples by cytology and/or FC.CONCLUSIONSIn patients with a previous history of lymphoma or a hematopoietic malignancy, a majority of the patients (59.4%) with an “atypical” or “suspicious” diagnosis on CSF will ultimately have malignant cells identified in the CSF by cytology and/or FC. Many of these patients can be identified more expediently with the concurrent utilization of flow cytometry. Cancer (Cancer Cytopathol) 2006. Published 2006 by the American Cancer Society.